COMPANY
Clinical Phase 1
Keywords: oncology neurology psychiatry solid tumors neurofibromatosis amyotrophic lateral sclerosis NF1 Mutation Neurofibroma Plexiform Plexiform Neurofibroma Neurofibromatosis Type 1 (NF1)-Related Plexiform Neurofibromas (PNs) Neurofibromatosis Type 1 (NF1) RAS Mutation RAF Mutation PAS-004
Location: Miami Beach, FL · source · Oct 15, 2026
Profile checked Oct 10, 2026
Timeline
- Raise Follow-on offering: $60M (total, as published), announced Dec 2, 2025. Source: company release on GlobeNewswire. source ↗
- Trial start Phase 1: PAS-004 in Adults Who Have Neurofibromatosis Type 1 With Plexiform Neurofibromas source ↗
- Raise Follow-on offering: $1.3M (total, as published), announced May 7, 2025. Source: company release on GlobeNewswire. source ↗
- Trial start Phase 1: PAS-004 in Patients With Advanced Solid Tumors source ↗
Upcoming milestones
- 2027-09 (ESTIMATED) · Phase 1 · PAS-004 in Adults Who Have Neurofibromatosis Type 1 With Plexiform Neurofibromas · NCT06961565
Estimated primary completion per ClinicalTrials.gov. Dates move.
Funding
Raised: $61.3M. Last 2 years.
- Follow-on offering: $60M (total, as published), announced Dec 2, 2025. Source: company release on GlobeNewswire. source ↗
- Follow-on offering: $1.3M (total, as published), announced May 7, 2025. Source: company release on GlobeNewswire. source ↗
Clinical trials (lead sponsor) 2
| Record | Title | Phase | Status | Start | Primary completion |
|---|
| NCT06961565 | PAS-004 in Adults Who Have Neurofibromatosis Type 1 With Plexiform Neurofibromas | Phase 1 | Recruiting | May 30, 2025 | 2027-09 (estimated) |
| NCT06299839 | PAS-004 in Patients With Advanced Solid Tumors | Phase 1 | Recruiting | Feb 29, 2024 | 2026-02 (estimated) |
